Visuals That Caught Our Eye, at the end, spotlights compelling charts and graphs that stood out this week
In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort (March 21, 2019) Once-Weekly Semaglutide in Adults with Overweight or Obesity (February 10, 2021) Semaglutide For The Treatment of Overweight and Obesity: A Review OZEMPIC (semaglutide) injection, for subcutaneous use
Here is why the formula works
A practical approach: schedule your injection on your rest day or the day before a lighter training session
Poison control centers have taken notice and reported their findings
